Chronic central infusion of orexin-A increases arterial pressure in rats

Brain Research Bulletin
Yingzi LinMitsuo Iida

Abstract

We determined the cardiovascular responses as well as food and water intakes to chronic intracerebroventricular administration of orexin-A and orexin-B for 14 days in conscious rats. Chronic intracerebroventricular infusion of orexin-A (50 pmol/h) elicited a significant increase in systolic blood pressure on the third day (+15.6 +/- 2.9 mm Hg), and during the continuous intracerebroventricular infusion of orexin-A the blood pressure returned to the baseline levels at day 14. In contrast, chronic intracerebroventricular infusion of orexin-B (50 pmol/h) failed to change systolic blood pressure during the 14 days of experimental periods. Chronic intracerebroventricular infusions of neither orexin-A nor orexin-B changed urinary catecholamine excretions, food and water intakes, and urine volumes at 7 and 14 days of infusion periods. Mean arterial pressure directly measured at 14 days did not differ among the groups of orexin-A, orexin-B, and artificial cerebrospinal fluid treatments. Both intravenous injections of pentolinium (5 mg/kg), a ganglion blocking agent, and CV-11974 (0.05 mg/kg), an AT(1) receptor antagonist, decreased arterial pressure; however, these responses were not different among the groups. These results suggest th...Continue Reading

References

Oct 10, 1997·Hypertension·W G HaynesA L Mark
Feb 21, 1998·Proceedings of the National Academy of Sciences of the United States of America·L de LeceaJ G Sutcliffe
Feb 7, 1998·Hypertension·E W ShekJ E Hall
Jan 20, 1999·Proceedings of the National Academy of Sciences of the United States of America·Y DateM Nakazato
Mar 5, 1999·Brain Research·D C SweetC M Kotz
May 13, 1999·Brain Research·T NambuK Goto
May 1, 2001·Journal of Neuroendocrinology·M JászberényiG Telegdy

❮ Previous
Next ❯

Citations

Feb 27, 2004·Physiology & Behavior·Robert Di NicolantonioMichal Pravenec
Nov 27, 2002·Neuropeptides·R J RodgersJ E Blundell
Jul 2, 2003·Regulatory Peptides·Kiyoshi MatsumuraMitsuo Iida
May 11, 2010·The Medical Clinics of North America·Michelle Cao
Oct 4, 2007·Frontiers in Neuroendocrinology·Kousaku Ohno, Takeshi Sakurai
Nov 17, 2004·Regulatory Peptides·Jon J RamseyAndrew G Swick
Sep 10, 2005·Journal of Clinical Neuroscience : Official Journal of the Neurosurgical Society of Australasia·Beng Ti AngIvan Ng
May 17, 2014·Frontiers in Neuroscience·Miles D ThompsonJyrki P Kukkonen
Jul 28, 2016·Molecular and Cellular Endocrinology·B MikuláškováJ Kuneš
May 17, 2017·Naunyn-Schmiedeberg's Archives of Pharmacology·Monika RaniPawan Krishan
Oct 28, 2016·Journal of Basic and Clinical Physiology and Pharmacology·Giovanni MessinaMarcellino Monda
Mar 30, 2017·Current Hypertension Reports·Roberta ImperatoreLuigia Cristino

❮ Previous
Next ❯

Related Concepts

Related Feeds

CSF & Lymphatic System

This feed focuses on Cerebral Spinal Fluid (CSF) and the lymphatic system. Discover the latest papers using imaging techniques to track CSF outflow into the lymphatic system in animal models.

Anthelmintics

Anthelmintics or antihelminthics are a group of antiparasitic drugs that expel parasitic worms (helminths) and other internal parasites from the body by either stunning or killing them and without causing significant damage to the host. Discover the latest research on anthelmintics here.

Antihypertensive Agents: Mechanisms of Action

Antihypertensive drugs are used to treat hypertension (high blood pressure) which aims to prevent the complications of high blood pressure, such as stroke and myocardial infarction. Discover the latest research on antihypertensive drugs and their mechanism of action here.